Meghana S. Pagadala

Predicting Neoantigen Immunogenicity from In Vivo Immune Editing

This paper introduces NEMo, a machine learning model that predicts neoantigen immunogenicity using in vivo immune editing data, showing improved stratification of progression-free survival across multiple clinical settings.

Association of HOXB13 G84E with prostate cancer among 592,158 men

This paper shows the HOXB13 p.G84E variant increases prostate cancer risk by threefold in men, but does not lead to more aggressive cancer.

Population-scale sequencing resolves correlates and determinants of latent Epstein-Barr Virus infection

The paper uses population-scale whole genome sequencing to identify EBV DNA as a biomarker for respiratory, autoimmune, and cardiovascular diseases and identifies genetic determinants of EBV persistence.

VADEr: Vision Transformer-Inspired Framework for Polygenic Risk Reveals Underlying Genetic Heterogeneity in Prostate Cancer

VADEr, a Vision Transformer-inspired framework, improves polygenic risk prediction for prostate cancer by capturing genetic interactions and revealing heterogeneity through DARTH scores.

Prevalence and disease risks for male and female sex chromosome trisomies: a registry-based phenome-wide association study in 1.5 million participants of MVP, FinnGen, and UK Biobank

This study identifies prevalence and disease risks for male and female sex chromosome trisomies using registry data from 1.5 million participants, finding shared phenotypic associations across trisomy subtypes.

Epigenetic Germline Variants Predict Cancer Prognosis and Risk and Distribute Uniquely in Topologically Associating Domains

This study shows that epigenetic variants affecting DNA methylation are distributed in chromatin domains and are linked to cancer risk and prognosis.

Prevalence, Morbidity, and Mortality of 1,609 Men with Diagnosed and Undiagnosed Sex Chromosome Aneuploidy: Results from the Diverse Million Veteran Program (MVP) Cohort

The paper examines the prevalence, morbidity, and mortality of sex chromosome aneuploidy in men from the MVP cohort, finding a prevalence of 1 in 370 males with higher healthcare utilization and poorer HRQoL but similar life expectancy compared to controls.